Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20117033 | 0.74 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HTR6MAPK1 | |
| SCHEMBL12723078 | 0.74 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3HTR6MAPK1 | |
| SCHEMBL24364555 | 0.72 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3HTR6MAPK1 | |
| SCHEMBL25152671 | 0.72 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3HTR6MAPK1 | |
| SCHEMBL25492728 | 0.71 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3HTR6MAPK1 | |
| SCHEMBL19174820 | 0.71 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3HTR6MAPK1 | |
| SCHEMBL13649123 | 0.69 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HTR6MAPK1 | |
| SCHEMBL19398853 | 0.69 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HTR6MAPK1 | |
| SCHEMBL19841838 | 0.69 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3HTR6MAPK1 | |
| SCHEMBL24364556 | 0.68 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3HTR6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265616-B1 | FURO-AND THIENO[3,2-C]PYRIDINES | OSI PHARM INC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-8022206-B2 | Furo[3,2-C]pyridines | OSI Pharmaceuticals, LLC (US) | 2011-09-20 | — | — | US | disclosed |
| EP-2265616-A1 | FURO-AND THIENO[3,2-C]PYRIDINES | OSI Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009100282-A1 | FURO-AND THIENO[3,2-C] PYRIDINES | OSI PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197864-A1 | Furo- and Thieno [3,2-c] Pyridines | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
| WO-2002058695-A9 | (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS | MERCK & CO INC (US) | 2003-09-12 | — | — | WO | disclosed |
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197864-A1 | Furo- and Thieno [3,2-c] Pyridines | RET, MET, ERBB2 | SLC6A2 4496/4885SLC6A4 4153/4885SLC6A3 2911/4885 |
| US-20030092712-A1 | (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents | MAPK1, MAPK7, MAPKAPK2 | SLC6A2 4059/4885SLC6A4 4291/4885SLC6A3 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.